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In Reply: Short Intensified 
Treatment in Children 
With Drug-Susceptible 
Tuberculous Meningitis
child effectively on isoniazid monotherapy 
for most of their treatment. This can be a 
problem in areas with high prevalence of iso-
niazid resistance. In addition, the poor CSF 
penetration of ethambutol2 renders its inclu-
sion in the regimen questionable.
The short intensified treatment regi-
men used in the Western Cape for nearly 2 
decades with higher isoniazid and rifampin 
dosages, longer administration of pyrazina-
mide and substitution of ethambutol with 
ethionamide provides higher CSF concentra-
tions of anti-tuberculosis drugs for the entire 
duration of treatment.2 It may also overcome 
isoniazid-monoresistance3 and children 
appear to tolerate combination treatment 
with pyrazinamide better than adults.
Twelve years before the most recent 
WHO recommendations in 2010, this group 
published their experience with the same treat-
ment regimen, showing that it was effective 
and associated with one of the lowest mortal-
ity rates reported.4 It is disappointing that this 
regimen has not been evaluated further in 
other centers and that most authorities still rec-
ommend only 2 months of intensive treatment.
Despite demonstrating good out-
comes and a shorter duration of treatment, 
the study by van Toorn is observational 
without a randomized control group for 
comparison; it thus may provide insufficient 
evidence to change international policy. In 
addition, the regimen employs a drug usu-
ally reserved for second-line treatment, 
which could have implications for accept-
ability by tuberculosis programs. Further, 
recent WHO dosing recommendations may 
make it difficult to use the higher dosages 
described in the study, given the shortage of 
single drug formulations in many settings.5
However, these operational obstacles 
should not impede the identification of the 
best possible treatment regimen. An appro-
priately powered randomized controlled trial 
to address this question is long overdue. One-
hundred eighty-four children with TBM were 
enrolled in this study from a single center in 
4 years; patient numbers, although limited, 
should not be an impediment to conducting a 
multicenter trial. Such a trial should compare 
the standard WHO-recommended regimen 
with a shortened regimen using drugs with 
good CSF penetration for the full duration. 
Consideration should be given to using a fluo-
roquinolone (levofloxacin or moxifloxacin) 
instead of ethionamide, as many pediatricians 
are hesitant to use ethionamide because of its 
side-effect profile as well as cross-resistance 
with isoniazid. Particular attention should 
be paid to using standardized assessments of 
neurologic outcome and toxicity and the issue 
of blinding. Until better evidence is provided, 
children with TBM will continue to be treated 
with what is likely to be a suboptimal regimen.
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To the Editors:
We read with interest the results of the study by van Toorn et al. describing 
short intensified treatment for children with 
drug-susceptible tuberculous meningitis 
(TBM).1 The paper raises important questions 
regarding the most appropriate antimicrobial 
treatment regimen for children with TBM.
The World Health Organization 
(WHO) recommends giving 2 months of iso-
niazid, rifampin, pyrazinamide and ethambu-
tol followed by 10 months of isoniazid and 
rifampin. After meningeal inflammation has 
subsided, rifampin has poor penetration into 
the cerebrospinal fluid (CSF)2 leaving the 
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Reply:
We agree with the North London TB journal club about the impor-
tance of trials that would determine the 
most appropriate antimicrobial regimen 
for children with tuberculous meningitis 
(TBM). The study design advocated by the 
authors is a randomized controlled trial 
(RCT) of short intensified versus standard 
treatment (as advised by the World Health 
Organization).
Although a RCT would be the pre-
ferred study method, a large sample size 
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